Vagus nerve stimulation

First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical’s Pioneering Technology for the Treatment of Rheumatoid Arthritis

Retrieved on: 
Monday, October 10, 2022
Medical Devices, Health, Health Technology, Clinical Trials, General Health, Biotechnology, Risk, Rheumatoid arthritis, Arthritis, Neck, Patient, Inflammation, University, Stage 2, Disability, Disease-modifying antirheumatic drug, University of New Mexico Hospital, CEO, Pain, Key Stage 1, Safety, ACR20, RA, American College of Rheumatology, Pharmacotherapy, Inflammatory bowel disease, Albuquerque Air Route Traffic Control Center, FDA, Vagus nerve stimulation, American College, Inflection point, Data analysis, Vagus nerve, Pharmaceutical industry, Dentistry, Rheumatology

The RESET-RA study is evaluating SetPoint Medical's investigational platform technology for treatment of rheumatoid arthritis (RA) using vagus nerve stimulation to activate innate anti-inflammatory pathways.

Key Points: 
  • The RESET-RA study is evaluating SetPoint Medical's investigational platform technology for treatment of rheumatoid arthritis (RA) using vagus nerve stimulation to activate innate anti-inflammatory pathways.
  • The company recently announced FDA approval for continuation to Stage 2 of the study based on outcomes from an interim data analysis.
  • We enrolled multiple patients in Stage 1 of the study, and are looking forward to contributing more participants in the second stage of the study.
  • The RESET-RA study is the first-of-its-kind study to evaluate vagus nerve stimulation for the treatment of RA.

Neurotech Company Neuvana Part of a Major National Research Grant Awarded to the University of Notre Dame

Retrieved on: 
Tuesday, October 4, 2022
Vagus nerve stimulation, Emotion, Intervention, Plasma protein binding, Technology, Psychology, Research, Life, SPIRIT, PALM, CEO, MD, Suicide Behaviors Questionnaire-Revised, Self-harm, Philosophy, LLC, Notre Dame, National, Science, Vagus nerve, Program, Boca Raton Regional Hospital, Suicide, Risk, University, Xen, GLOBE, Management, Neuroscience

WEST PALM BEACH, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Neuvana , a South Florida-based neurotech company, is proud to announce its flagship product, Xen, will be part of a $4 million research grant awarded to the University of Notre Dame , the recipient of the Transformative Research Award from the National Institutes of Health .

Key Points: 
  • WEST PALM BEACH, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Neuvana , a South Florida-based neurotech company, is proud to announce its flagship product, Xen, will be part of a $4 million research grant awarded to the University of Notre Dame , the recipient of the Transformative Research Award from the National Institutes of Health .
  • Xen is the first-of-its-kind product available to consumers that targets the vagus nerve through electrical stimulation to help regulate the bodys nervous system.
  • For more information about the product, visit www.neuvanalife.com and to learn more about Notre Dames SPIRIT program, visit https://preventsuicide.nd.edu .
  • Neuvana, LLC is a South Florida-based company at the intersection of wellness andtechnology, with a focus on Neuroscience.

ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

Retrieved on: 
Thursday, September 22, 2022
Diabetes, Health, Safety, Coma, Small Business Innovation Research, Blood, Metabolic disorder, Weight loss, FDA, Vagus nerve stimulation, Ramakanta Panda, PVN, Company, Miniature pig, Obesity, Stroke, Bluetooth, Pancreas, Patient, Reshaping Cultural Policies, Lists of diseases, Insulin, Technology, Type 2 diabetes, SBIR, Private sector, Nasdaq, Liver, CGM, Hypoglycemia, Collection, SAN, IPG, GLOBE, AI, NIH, Anatomy, Stomach, Pharmaceutical industry, Medical device

Specifically, the grant will fund development of the device for the treatment of hypoglycemia.

Key Points: 
  • Specifically, the grant will fund development of the device for the treatment of hypoglycemia.
  • The ReShape DBSN utilizes hypoglycemia vagal nerve stimulation (HVNS) using an implantable pulse generator (IPG) in a closed loop with a continuous glucose monitor (CGM).
  • The technology has demonstrated safety and efficacy through experiments in diabetic swine utilizing a previous Phase I funding from a NIH SBIR grant.
  • The award of our second NIH SBIR grant is a testament to the strength of the commercial opportunity of our novel DBSN device to address the significant, global diabetes market, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.

MicroTransponder Completes $73M Series E Financing

Retrieved on: 
Wednesday, September 21, 2022
U.S. Venture Partners, VNS, FDA, Vagus nerve stimulation, Organization, Survivor, Intellectual property, COO, Stroke, Therapy, CEO, Technology, Research, Rehabilitation, Boston Scientific, Prashant Singh Rawat, Patent, Pharmaceutical industry, Medical device, Rawat

AUSTIN, Texas, Sept. 21, 2022 /PRNewswire/ -- MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO). The funding supports the market development and commercialization of MicroTransponder's FDA-approved Vivistim® Paired VNS™ System, a first-of-its-kind breakthrough technology that uses vagus nerve stimulation (VNS) during rehabilitation therapy to improve upper limb function for stroke survivors.

Key Points: 
  • AUSTIN, Texas, Sept. 21, 2022 /PRNewswire/ -- MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO).
  • The company's Series E was led by US Venture Partners , a multi-stage investment firm.
  • For more information about MicroTransponder and the first FDA-approved use of vagus nerve stimulation for stroke rehabilitation, visit Vivistim.com.
  • MicroTransponder, Inc. is a privately held, global medical device company based in Austin, Texas, committed to developing research-based neuroscience solutions.

Nordson Corporation Appoints Milton Morris to Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Packaging, Electronic Design Automation, Semiconductor, Engineering, Technology, Manufacturing, Electronics, VNS, NYSE, Vagus nerve, LLC, Conditional sentence, Corporation, Organization, Company, Vagus nerve stimulation, Industry, Arrhythmia, EMBC, Program, Patient, NDSN, Technology, Nasdaq, Solution, NASDAQ, Research, Boston Scientific, Marketing, BSX, Management, Medical device, Nordson Corporation

Nordson Corporation (NASDAQ: NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors.

Key Points: 
  • Nordson Corporation (NASDAQ: NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors.
  • Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board.
  • We look forward to bringing Miltons perspective to the board, said Michael Merriman, chair of the board of directors, Nordson Corporation.
  • I look forward to partnering with the Nordson board of directors and executive management team.

SetPoint Medical Announces FDA Approval for Continuation of the RESET-RA Pivotal Study

Retrieved on: 
Tuesday, September 13, 2022
FDA, Medical Devices, Health, Clinical Trials, Health Technology, Safety, Risk, MD, FDA, Food, Vagus nerve stimulation, Inflammatory bowel disease, IDE, Rheumatoid arthritis, Review, Inflection point, 2009 Vuelta a España, Stage 1 to Stage 11, Patient, Vagus nerve, RA, Disease-modifying antirheumatic drug, Pharmacotherapy, Food and Drug Administration, Stage 2, ACR20, Pharmaceutical industry

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune disease, announced U.S. Food and Drug Administration (FDA) approval for continuation of the companys RESET-RA study.

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune disease, announced U.S. Food and Drug Administration (FDA) approval for continuation of the companys RESET-RA study.
  • The FDA approved study continuation with no changes to the study protocol following their review of both safety and efficacy outcomes from Stage 1.
  • This is another significant milestone for SetPoint Medical as we continue to develop this novel treatment option for RA patients, said David Chernoff, MD, Chief Medical Officer of SetPoint Medical.
  • The RESET-RA study is the first of its kind study to evaluate vagus nerve stimulation for treatment of RA.

Nerve Repair & Regeneration Market Forecast: Increasing R&D Investments & Research Expenditure to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Health, Other Health, CAGR, Regeneration, Government, Injury, Lists of diseases, Research, Growth, USD, Investment, Incidence, Vagus nerve stimulation, Deep brain stimulation, Application, Asia-Pacific

The global nerve repair & regeneration market is expected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 12.1%.

Key Points: 
  • The global nerve repair & regeneration market is expected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 12.1%.
  • The growth in this market is driven by increasing research expenditure on the neurological disorders by the government, the increasing R&D investments by the market players into the neuromodulation and neurostimulation devices and the biomaterials.
  • Also, the expanding geriatric population base dries the growth of the market by placing more demand of the nerve repair and regeneration products.
  • Based on product type, the nerve repair and regenerations market is segmented into neurostimulation and neuromodulation devices and biomaterials.

MicroTransponder Raises $53M, Appoints New CEO

Retrieved on: 
Monday, June 20, 2022
Survivor, FDA, Learning, Stroke, Lancet, Guidant, U.S. Venture Partners, Rehabilitation, Foust, CEO, Hand, Research, Marketing, Quality of life, USVP, Hobby, Vagus nerve stimulation, Standard of care, Love, Pharmaceutical industry, Medicine, Medical device

MicroTransponder announced seasoned medical device executive Richard Foust as CEO and Director.

Key Points: 
  • MicroTransponder announced seasoned medical device executive Richard Foust as CEO and Director.
  • "Our investors are energized by MicroTransponder's vision to enable treatment for the millions of stroke survivors that have ongoing moderate to severe upper limb impairment.
  • "I'm enthusiastic about the MicroTransponder team and the success they have had in building the clinical foundation for Vivistim," said Tansey.
  • MicroTransponder, Inc. is a privately held, global medical device company based in Austin, Texas, committed to developing research-based neuroscience solutions.

Feinstein Institutes for Medical Research and Spark Biomedical, Inc. advance bioelectric medicine designed to stem excessive blood loss

Retrieved on: 
Thursday, June 2, 2022
Â, Litre, NIDA, Tan, Ambulance, DARPA, Trauma, Nursing, Feinstein Institute for Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Bleeding time, Northwell Health, Medical research, Medicine, History, Opioid, Cancer, Hospital, Sparrow, Spleen, CEO, Genetics, Operating theater, Quality of life, Molecular medicine, Mental health, VNS, Bleeding, Physician, Patient, Vagus nerve stimulation, Metabolic pathway, Science, PTSD, Adult, Research, Feinstein, LinkedIn, Miniature pig, FDA, GLOBE, Twitter, Clinical trial, Hemostasis, Instagram, Autoimmunity, Pharmaceutical industry, MD, Facebook, Shock

Trauma scenes: First responders could apply the device to trauma victims at accident scenes or in ambulances to slow blood loss prior to hospitalization.

Key Points: 
  • Trauma scenes: First responders could apply the device to trauma victims at accident scenes or in ambulances to slow blood loss prior to hospitalization.
  • Military missions: Before missions where there is potential for physical trauma, soldiers could apply the device prophylactically to curb blood loss if they are wounded.
  • We look forward to working with all of the great scientists at the Feinstein Institutes to realize a life-saving vision set forth over a decade ago.
  • Were making breakthroughs in medicine at the Feinstein Institutes for Medical Research.

First Commercial Vivistim Patient Set to Begin Paired VNS Therapy for Improved Upper Limb Function Post Stroke

Retrieved on: 
Wednesday, May 11, 2022
Arm, Rancho Los Amigos National Rehabilitation Center, Los Angeles County Department of Health Services, Rehabilitation, Brain, Vagus nerve stimulation, Keck Hospital of USC, Clinical trial, Stroke, VNS, Hand, Inc., FDA, Ascending limb of loop of Henle, Hair, Skin, Quality of life, Survivor, Solution, Vagus nerve, News, CEO, Univision, Exercise, Pharmaceutical industry, Healthcare, Medicine, Dietary supplement, Medical imaging, Toy, Lancet, USC, MD, Villalpando, Turner

MicroTransponder, Inc. reached a milestone Tuesday with the first commercial use of its Vivistim Paired VNS System.

Key Points: 
  • MicroTransponder, Inc. reached a milestone Tuesday with the first commercial use of its Vivistim Paired VNS System.
  • "Stroke survivors whose hand and arm function have not significantly improved can now collaborate with their healthcare professionals to assess if they are potential candidates for Vivistim."
  • When used in conjunction with rehabilitation therapy, the Vivistim System employs paired vagus nerve stimulation (VNS) to generate two to three times more hand and arm function improvement for stroke survivors than rehabilitation therapy alone1.
  • Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial.